Found this on Seeking Alpha from last month. Might give some indication as to what our (ACL) fonda business may be worth.
More on GSK (GSK -0.3%) / Aspen (APNHF.PK) deal: Reuters speculates that GSK's sale of its thrombosis drug brands Arixtra and Fraxiparine to Aspen could be worth £700M, or twice this year's anticipated sales of around £350M. That would be down from £420M in 2013 and £510M in 2011. Around 1,000 GSK workers, mostly in France, would transfer to Aspen. News of the prospective sale prompted speculation that GSK may look to offload other older drugs. This Market Current was sent to 7,264 people who get email alerts on GSK.
Found this on Seeking Alpha from last month. Might give some...
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable